Time-resolved FRET reports FGFR1 dimerization and formation of a complex with its effector PLCγ1 by Perdios, L et al.
	  	  
Supplementary	  material	  	  
	  
Table	  of	  contents	  	  
• Supplementary	  Experimental	  Procedures	  
• Supplementary	  References	  	  
• Supplementary	  Figure	  Legends	  	  
• Supplementary	  Figures	  S1,	  S2,	  S3	  and	  S4	  
	   	  
	  Supplementary	  Experimental	  Procedures	  
	  
Expression	  of	  recombinant	  proteins	  
For	   expression	  of	  His6.Stag.3C.GyrB.FGFR1KD.TC	   {which	  encodes	  N-­‐terminally	   hexahistidine	   tag,	   S-­‐tag,	  
3C	  protease	  recognition	  sequence,	  DNA	  gyrase	  B	  (GyrB)	  domain,	  FGFR1KD-­‐3F-­‐0P	  [457–774,	  (Y463,	  583,	  
585F)	   (L457V,	   C488A,	   C584S)]	   and	   fluorescein	   arsenical	   hairpin	   binder	   (FlAsH)	   amino	   acid	   sequence	  
(FLNCCPGCCMEP)}	  from	  pTriExTM4	  (Novagen)	  vector	  backbone.	  Constructs	  were	  heat-­‐shock	  transformed	  
into	   E.coli	   strain	   C41	   (DE3)	   with	   pTriExTM4-­‐	   His6.Stag.3C.GyrB.FGFR1KD.TC	   and	   pDUET-­‐Cdc37-­‐λPPase	  
(which	   encodes	   lambda	   protein	   phosphatase	   (λPPase),	   an	   enzyme	   that	   hydrolyses	   phosphorylated	  
tyrosines	  and	  Hsp90	  co-­‐chaperone	  Cdc37,	  which	  promotes	  the	  stability	  of	  kinase	  domains).	  Cells	  were	  
recovered	   in	   1	   ml	   of	   SOC	   media	   for	   1	   h	   at	   37	   ºC,	   and	   plated	   on	   terrific	   broth	   (TB)	   agar	   plates	  
supplemented	  with	  ampicillin	  (50	  μg/mL),	  spectinomycin	  (50	  μg/mL)	  and	  10	  mM	  glucose.	  Colonies	  were	  
inoculated	  into	  500	  ml	  of	  TB	  with	  ampicillin	  (50	  μg/mL)	  and	  spectinomycin	  (50	  μg/mL)	  and	  grown	  to	  an	  
OD600	   of	   1.0.	   Cultures	   were	   cooled	   to	   15°C	   and	   expression	   was	   induced	   with	   100	   μM	   IPTG	   for	  
approximately	  16	  hours.	  Cells	  were	  harvested	  by	  centrifugation	  and	  frozen	  at	  -­‐80	  ºC	  until	  processed.	  
	  
600	   μL	   of	   Ni2+-­‐NTA	   beads	   (Qiagen)	   were	   added	   to	   the	   extract	   and	   the	   mixture	   was	   incubated	   with	  
agitation	  for	  1	  h	  at	  4	  ºC.	  Beads	  were	  collected	  by	  centrifugation	  (10	  min,	  1000	  g).	  The	  beads	  were	  three	  
times	  resuspended	  in	  30	  mL	  wash	  buffer	  (20	  mM	  Tris-­‐HCl,	  30	  mM	  imidazole,	  300	  mM	  NaCl,	  pH	  8.0)	  and	  
spun	   down	   at	   1000g.	   Subsequently,	   the	   beads	   were	   resuspended	   in	   10	   mL	   of	   wash	   buffer	   and	  
transferred	  to	  a	  column.	  The	  protein	  was	  eluted	  with	  3	  ml	  of	  wash	  buffer	  supplemented	  with	  200	  mM	  
imidazole	  and	  further	  purified	  by	  size-­‐exclusion	  chromatography	  employing	  a	  HiLoad	  16/60	  Superdex	  75	  
Prep	  Grade	  column	  (GE	  Life	  Sciences)	  at	  a	  flow	  rate	  of	  1	  mL/min	  (buffer:	  20	  mM	  Tris-­‐HCl,	  100	  mM	  NaCl,	  
2	  mM	  EDTA,	  pH	  7.4).	  Fractions	  containing	  the	  protein	  were	  pooled	  and	  concentrated	  with	  an	  Amicon	  
Ultra-­‐15	  3	  kDa	  MWCO	  centrifugal	  filter	  device	  (Millipore).	  Purified	  proteins	  were	  analyzed	  by	  10%	  SDS-­‐
PAGE	  and	  their	  mass	  confirmed	  by	  mass	  spectrometry	  (see	  Supplementary	  Information).	  
	  
Purification	  of	  recombinant	  proteins	  	  
For	   purification	   of	   protein	   domains	   expressed	   in	   C41	   (DE3)	   or	   BL21	   (DE3).	   Pellets	   derived	   from	   1	   L	  
cultures	  were	  thawed	  on	  ice	  and	  resuspended	  in	  20	  ml	  of	  chilled	  lysis	  buffer	  (25	  mM	  Tris-­‐HCl,	  250	  mM	  
NaCl,	   40	   mM	   imidazole,	   10	   mM	   benzamidine,	   100	   μg/ml	   lysozyme,	   pH	   8.0).	   Resuspension	   was	  
accomplished	  by	  placing	  the	  pellets	  on	  an	  orbital	  shaker	  at	  150	  rpm	  at	  4	  °C	  for	  30	  minutes.	  	  A	  solution	  of	  
10%	  (v/v)	  Triton-­‐X-­‐100	  and	  1	  K	  unitz	  of	  bovine	  pancreatic	  DNAse	  I	  was	  added	  and	  the	  lysate	  was	  placed	  
on	  the	  orbital	  shaker	  at	  150	  rpm	  at	  4°C	  for	  1	  hour.	  Cell	  lysates	  were	  clarified	  by	  centrifugation	  at	  13,000	  
rpm	  at	   4°C	   for	   1	   hour	   in	   an	   SS34	   rotor	   (Sorvall).	   The	   clarified	   lysate	  was	   loaded	   onto	   a	   5-­‐ml	  HisTrap	  
(HiTrap	  Chelating	  HP,	  GE	  Healthcare)	  on	  an	  Akta	  Explorer	  system	  (GE	  Healthcare)	  using	  His	  Buffer	  A	  (25	  
mM	   Tris-­‐HCl,	   500	   mM	   NaCl,	   40	   mM	   Imidazole,	   1	   mM	   TCEP,	   pH	   8.0).	   Non-­‐specific	   binding	   of	   other	  
proteins	   was	   removed	   by	   washing	   the	   column	   with	   10	   column	   volumes	   of	   His	   Buffer	   A.	   His-­‐tagged	  
proteins	  were	  collected	  by	  eluting	  with	   linear	   imidazole	  gradient	  from	  His	  Buffer	  A	  to	  His	  Buffer	  B	  (25	  
mM	  Tris-­‐HCl,	  500	  mM	  NaCl,	  500	  mM	   imidazole,	  1	  mM	  TCEP,	  pH	  8.0)	  over	  5	  column	  volumes.	  Protein	  
concentrations	   from	   the	   eluent	   were	   measured	   with	   a	   Nanodrop	   (ThermoScientific).	   The	   pooled	  
fractions	   containing	   the	   target	   protein	   were	   further	   incubated	   with	   10	   μg	   of	   protease	   per	   1	   mg	   of	  
protein	  (Ulp1	  protease	  for	  His6-­‐Sumo,	  and	  3C	  protease	  for	  His6-­‐3C)	  overnight	  at	  4◦C	  to	  cleave	  of	  the	  N-­‐
terminal	  fusion	  tag.	  The	  protein/protease	  mix	  was	  dialysed	  overnight	  at	  4	  °C	  against	  500	  ml	  of	  Dialysis	  
Buffer	   (25	  mM	  Tris-­‐HCl,	   150	  mM	  NaCl,	   10	  mM	   Imidazole	  and	  1	  mM	  TCEP,	  pH	  8.0).	   Separation	  of	   the	  
cleaved	   tag	   was	   achieved	   by	   reverse	   HisTrap	   chromatography	   over	   the	   5	   ml	   HisTrap	   column	   and	  
material	   that	   did	   not	   bind	   was	   collected.	   Subsequently,	   proteins	   were	   further	   purified	   by	   strong	  
quaternary	  ammonium	  (Q)	  anion	  exchange	  chromatography	  on	  a	  5	  ml	  HiTrap	  Q	  column	  (GE	  Healthcare)	  
in	  Q	  Buffer	  A	  (25	  mM	  Tris-­‐HCl,	  20	  mM	  NaCl,	  1	  mM	  TCEP,	  pH	  8.0)	  and	  eluted	  with	  a	  linear	  gradient	  of	  10–
20	   column	  volumes	   to	  50%	  of	  Q	  Buffer	  B	   (25	  mM	  Tris-­‐HCl,	   1	  M	  NaCl,	   1	  mM	  TCEP,	  pH	  8.0).	   Fractions	  
containing	  the	  target	  protein	  were	  pooled,	  concentrated	  in	  spin	  concentrators	  (Vivaproducts)	  and	  then	  
further	  purified	  by	  size	  exclusion	  chromatography	  on	  a	  Superdex	  200	  10/300	  GL	  column	  (GE	  Healthcare)	  
using	  Gel	  Filtration	  Buffer	  (25	  mM	  Tris-­‐HCl,	  150	  mM	  NaCl,	  1	  mM	  TCEP,	  pH	  8.0).	  Fractions	  were	  collected,	  
combined	  and	  concentrated	   in	  spin	  concentrators,	  snap	  frozen	   in	   liquid	  nitrogen	  and	  stored	  at	  -­‐80	  °C.	  
Purified	  proteins	  were	  analyzed	  by	  10%	  SDS-­‐PAGE.	  
	  
Cloning,	  expression	  and	  purification	  of	  recombinant	  proteins	  
	  
PCR	  reactions	  were	  carried	  out	  on	  G-­‐STORM	  thermal	  cycler,	  followed	  by	  digests	  using	  DpnI	  (NEB).	  The	  
final	   reaction	   was	   transformed	   into	   E.coli	   XL10-­‐Gold	   (Stratagene).	   Colonies	   were	   picked,	   plasmid	  
prepared	  (QIAprep	  Spin	  Miniprep	  Kit,	  Qiagen)	  and	  sequenced	  after	  manipulation	  (BigDye3.1,	  ABI	  PRISM)	  
to	  ensure	  sequence	  fidelity.	  
	  
Kinase	  assays	  
In	   vitro	   kinase	   assays	   of	   recombinant	   proteins	   were	   carried	   out	   using	   ADP-­‐Glo™	   Kinase	   Assay	  
(Promega).The	  assays	  were	  carried	  out	  at	  25°C	  in	  40	  mM	  Tris-­‐HCl	  pH	  8.0,	  20	  mM	  MgCl2,	  20	  mM	  NaCl,	  
100	  μM	  TCEP,	   and	  100	  μM	  Na3VO4,	   in	   a	   total	   volume	  of	   60	  μl	   (15	  μl	   kinase	   reaction;15	  μl	  ADP-­‐Glo™	  
Reagent;	  30	  μl	  Kinase	  Detection	  Reagent)	  in	  solid	  white,	  flat-­‐bottom	  96-­‐well	  plates.	  Poly	  (E4Y1)	  peptide	  
(Sigma-­‐Aldrich)	   and	   PLCγSA	  WT	  were	   used	   as	   substrates.	   The	   latter	   is	   an	   appropriate	   substrate	   since	  
during	   physiological	   activation	   of	   PLCγ	   by	   FGFR,	   the	   interaction	   of	   activated	   FGFR1	   is	   centred	   on	   the	  
nSH2	   of	   PLCγ,	  while	   phosphorylation	   occurs	   on	   residue	   Y783.	   Tyrosine	   phosphatase	   inhibitor	   sodium	  
orthovanadate	  was	  used	  in	  the	  buffer	  system	  to	  preserve	  the	  protein	  tyrosyl	  phosphorylation	  state	  and	  
allow	  activation	  of	  FGFR1KD	  in	  the	  absence	  of	  ligand	  HSPG	  (Gherzi	  1988,	  Posner	  1994).	  Kinase	  reactions	  
were	  stopped	  after	  30	  minutes	  of	   incubation	   for	  enzyme	  titration	  and	  autophosphorylation	  reactions,	  
and	  after	  60	  minutes	  for	  inhibitor	  dose	  response	  titrations.	  ATP-­‐to-­‐ADP	  standard	  conversion	  curves,	  Z-­‐
values	   and	   signal-­‐to-­‐background	   ratio	   were	   calculated	   according	   to	   the	   manufacturer’s	   published	  
procedure	   in	  order	   to	  assess	   the	   linearity	  of	   the	  assay	  and	   to	   calculate	   the	  amount	  of	  ADP	  produced	  
during	  enzymatic	  titrations.	  Z'	  values	  were	  calculated	  for	  5	  –	  100%	  ATP	  conversion	  using	  50	  µM	  ATP.	  For	  
determinations	   of	   Km	   of	   the	   ATP	   (Km,	   ATP)	   concentration	   that	   should	   be	   used,	   reactions	   contained	   a	  
peptide	  concentration	  of	  0.2	  μg/μl	  and	  ATP	  at	  varying	  concentrations	  of	  10–240	  μM.	  The	  assay	  signal	  in	  
the	   presence	   of	   increasing	   ATP	   concentrations	   was	   measured	   and	   fitted	   to	   the	   Michaelis–Menten	  
equation.	  The	  optimal	  kinase	  amount	  was	  determined	  when	  50%	  of	  substrate	  conversion	  was	  achieved	  
(half	  maximal	   reaction	  velocity,	  ½Vmax),	  and	  assays	  were	  carried	  out	  at	   the	  apparent	  Km,	   ATP,	  at	  50	  µM	  
ATP.	   Negative	   control	   experiments	   were	   performed	   in	   the	   absence	   of	   ATP,	   substrate,	   enzyme	   and	  
positive	   controls	   were	   performed	   with	   FGFR1KD	   WT	   (data	   not	   shown).	   Luminescence	   output	   was	  
recorded	   using	   BMG	   Labtech	   FLUOstar	   Optima	   plate	   reader	   at	   520nm.	   Apparent	   IC50	   values	   were	  
calculated	   by	   detecting	   the	   decrease	   in	   phosphorylation	   of	   Poly	   (E4Y1)	   upon	   kinase	   inhibition	   using	  
AZD4547	   and	   PD173074.	   Curve	   fitting	   for	   inhibitor	   dose	   response	   titration	   was	   performed	   using	  
GraphPad	   Prism®	   sigmoidal	   dose-­‐response	   (variable	   slope)	   software.	   Apparent	   IC50	   values	   were	   then	  
used	  to	  measure	  the	  approximate	  inhibitor	  constant	  value	  (Ki)	  using	  the	  Cheng–Prusoff	  equation,	  which	  
describes	   the	  dependencies	  between	   IC50	  value	  and	  ATP	  concentration	   for	  ATP-­‐competitive	   inhibitors.	  
Error	  bars	  indicate	  the	  SDs	  of	  three	  replicates.	  
	  
SDS-­‐PAGE	  and	  Western	  blotting	  	  
Sample	  buffer	  (4x	  stock:	  62.5	  mM	  Tris.HCl,	  2%	  SDS,	  25%	  glycerol,	  0.01%	  Bromophenol	  blue,	  0.25	  M	  DTT,	  
pH	  6.8)	  was	  added	  to	  protein	  samples	  to	  1x.	  Protein	  denaturation	  was	  performed	  at	  100°C	  for	  5	  minutes	  
for	   optimal	   sample	   migration.	   Protein	   samples	   were	   separated	   by	   electrophoresis	   through	   sodium	  
dodecyl	   sulphate	   polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE)	   and	   transferred	   to	   a	   polyvinylidene	  
fluoride	  (PVDF)	  membrane	  (equilibrated	  in	  methanol)	  (Millipore)	  using	  a	  standard	  wet	  transfer	  method	  
(buffer:	   50	   mM	   Tris-­‐HCl,	   380	   mM	   glycine	   and	   20%	   methanol).	   For	   pull-­‐down	   assays,	   proteins	   were	  
visualised	  by	  Amido	  Black	  staining.	  For	  immunoblotting,	  the	  membranes	  were	  blocked	  with	  5%	  non-­‐fat	  
dry	  milk	   (Marvel)	   in	  TBS	  pH	  7.5	   containing	  0.1%	  Tween-­‐20	   (Sigma-­‐Aldrich)	   (TBS-­‐T)	   for	  30-­‐60	  min	  with	  
agitation.	   Membranes	   were	   incubated	   with	   the	   indicated	   primary	   antibodies	   for	   1	   hour	   at	   room	  
temperature	  or	  overnight	   incubation	  at	  4°C.	  Membranes	  were	  washed	  three	  times	   for	  5	  min	   in	  TBS-­‐T	  
followed	  by	  incubation	  with	  required	  conjugate	  diluted	  in	  5%	  milk/TBS-­‐T	  for	  1	  hour	  with	  agitation.	  Blots	  
were	  subject	   to	   three	  washes	   in	  TBS-­‐T	  and	  developed	  using	  with	  ECL	  prime	  detection	  kit	   (Pierce)	  and	  
exposed	  to	  Hyperfilm	  ECL	  (Amersham	  Biosciences).	  
	  
In-­‐gel	  fluorescence	  of	  GyrB.FGFR1KD.TC	  with	  FlAsH-­‐EDT2	  or	  ReAsH-­‐EDT2	  
FlAsH-­‐EDT2	  (10	  –	  100	  μM)	  or	  ReAsH-­‐EDT2	  (10	  –	  50	  μM)	  were	  added	  to	  Laemmli	  sample	  buffer	  [4x	  stock:	  
62.5	  mM	  Tris.HCl	   pH	   6.8,	   2%	   SDS,	   25%	   glycerol,	   0.01%	  Bromophenol	   blue,	   50	  mM	  TCEP	   (neutralized	  
with	  3.5	  equiv	  of	  Tris.HCl	  pH	  8.0)].	  The	  protein	  and	  sample	  buffer	  were	  kept	  at	  room	  temperature	  for	  
15-­‐30	  min	   and	   loaded	   onto	   the	   SDS-­‐PAGE	   that	  was	   run	   as	   usual.	   The	   protein-­‐FlAsH	   complexes	  were	  
visualized	  on	  the	  unstained	  or	  unfixed	  gel	  by	  illumination	  with	  either	  an	  ultraviolet	  light-­‐box	  or	  by	  using	  
a	  CCD	  camera	  with	  appropriate	  filters	  for	  fluorescence	  of	  FlAsH	  (excitation:	  511	  nm,	  emission:	  527	  nm)	  
or	  ReAsH	  (excitation:	  593	  nm,	  emission:	  608	  nm).	  
	  
Native	  Mass	  Spectroscopy	  
Samples	  were	  analysed	  by	  HPLC,	  using	  a	  Waters	  Premier	  quadrupole	  time	  of	  flight	  (Q-­‐Tof)	  system	  with	  a	  
Waters	  2795XC	  Separations	  Module	  and	  Waters	  Symmetry	  ®	  C18	  column	  (2.1x100	  mm,	  3.5	  μm).	  Mobile	  
phase	  A	  (water	  +	  0.1%	  formic	  acid)	  and	  mobile	  phase	  B	  (acetonitrile	  +	  0.1%	  formic	  acid)	  were	  used	  with	  
a	  flow	  rate	  of	  600	  μL/min,	  column	  temperature	  of	  40	  oC	  and	  injection	  volume	  of	  5	  –	  10	  μL	  (~20	  μg	  of	  
protein	  at	  ~1	  mg/mL	  [5	  μM]).	  Positive	  Ion	  Electrospray	  ionization	  mode	  on	  a	  Waters	  Micromass	  ®	  Q-­‐Tof	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Supplementary	  figure	  legends	  
	  
Supplementary	   Figure	   S1.	   (A)	   SEC	   molecular	   weight	   standards	   as	   determined	   on	   a	   Superdex	   200	  
column.	   (B)	   Elution	   profile	   of	   the	   GyrB-­‐FGFR1KD.TC	   monomer	   as	   determined	   on	   a	   Superdex	   200	  
column.	  
Supplementary	  Figure	  S2.	  Specific	  and	  quantitative	  labelling	  of	  GyrB.FGFR1KD.TC	  upon	  incubation	  with	  
FlAsH-­‐EDT2	  demonstrated	  by	  SDS-­‐PAGE	  (Coomassie	  staining	  and	  in-­‐gel	  fluorescence).	  
	  
Supplementary	  Figure	  S3.	  (A)	  (B)	  Inhibitor	  dose	  response	  titration	  of	  GyrB.FGFR1KD.TC	  in	  the	  presence	  
of	  50	  μM	  ATP,	  0.2	  μg/μl	  PolyE4Y1	  peptide	  and	  inhibitor	  PD173074	  at	  varying	  concentrations	  of	  	  0.8	  –	  500	  
nM	   (FGFR1	   IC50	   =	   ~22	   nM).	   Kinase	   inhibition	   was	   measured	   by	   detecting	   the	   decrease	   in	  
phosphorylation	  of	  PolyE4Y1	  after	  1	  hour.	  Maximal	  activity	  of	  GyrB.FGFR1KD.TC	  and	  background	  signal	  
were	  measured	  in	  the	  absence	  of	  inhibitor	  PD173074.	  
	  
Supplementary	   Figure	   S4.	   Complex	   formation	   of	   FGFR1KD	  with	   mTFP.nSH2	   and	   artificial	   dimerization	   as	  
observed	  by	  chromatography	  	  
(A)	   Complex	   formation;	   Elution	   profiles	   of	   the	   GyrB.FGFR1KD.TC-­‐mTFP.nSH2	   complex	   (blue)	   and	   the	  
excess	  nSH2	  (pink)	  with	  50	  μM	  ATP/20	  mM	  MgCl2	  as	  determined	  on	  a	  Superdex	  200	  column.	  
(B)	  Elution	  profiles	  of	  the	  GyrB.FGFR1KD.TC	  dimer	  (green)	  and	  the	  GyrB.FGFR1KD.TC	  monomer	  (yellow)	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